Comparative distribution of IPI and LLMPP signature score among patients in the low- and high-risk groups identified by CART
| . | Study cohort, no. (%) . | Low GPX1/ABCB1, no. (%) . | High GPX1/GSTA1, no. (%) . |
|---|---|---|---|
| IPI | |||
| 1 | 45 (39) | 11 (37) | 13 (52) |
| 2 | 27 (23) | 8 (27) | 6 (24) |
| 3 | 32 (28) | 8 (27) | 2 (8)* |
| 4 | 12 (10) | 3 (10) | 4 (16) |
| LLMPP | |||
| GCB | 64 (49) | 20 (59) | 12 (43) |
| ABC | 24 (18) | 7 (21) | 4 (14) |
| Type 3 | 42 (32) | 7 (21) | 12 (43) |
| . | Study cohort, no. (%) . | Low GPX1/ABCB1, no. (%) . | High GPX1/GSTA1, no. (%) . |
|---|---|---|---|
| IPI | |||
| 1 | 45 (39) | 11 (37) | 13 (52) |
| 2 | 27 (23) | 8 (27) | 6 (24) |
| 3 | 32 (28) | 8 (27) | 2 (8)* |
| 4 | 12 (10) | 3 (10) | 4 (16) |
| LLMPP | |||
| GCB | 64 (49) | 20 (59) | 12 (43) |
| ABC | 24 (18) | 7 (21) | 4 (14) |
| Type 3 | 42 (32) | 7 (21) | 12 (43) |
Data available on 116 subjects for IPI and 130 subjects for LLMPP signature. Percentages reflect distribution of patients in each cohort.
Significantly different from entire cohort; Fisher exact for heterogeneity (P = .048).